首页> 外文期刊>Infection and immunity >A Burkholderia pseudomallei ΔpurM Mutant Is Avirulent in Immunocompetent and Immunodeficient Animals: Candidate Strain for Exclusion from Select-Agent Lists
【24h】

A Burkholderia pseudomallei ΔpurM Mutant Is Avirulent in Immunocompetent and Immunodeficient Animals: Candidate Strain for Exclusion from Select-Agent Lists

机译:Burkholderia pseudomalleiΔpurM突变体在免疫能力强和免疫缺陷的动物中无毒:候选菌株被排除在选择代理人名单之外

获取原文
           

摘要

Burkholderia pseudomallei causes the disease melioidosis in humans and is classified as a category B select agent. Research utilizing this pathogen is highly regulated in the United States, and even basic studies must be conducted in biosafety level 3 (BSL-3) facilities. There is currently no attenuated B. pseudomallei strain available that is excluded from select-agent regulations and can be safely handled at BSL-2 facilities. To address this need, we created Bp82 and Bp190, which are ΔpurM derivatives of B. pseudomallei strains 1026b and K96243 that are deficient in adenine and thiamine biosynthesis but replication competent in vitro in rich medium. A series of animal challenge studies was conducted to ensure that these strains were fully attenuated. Whereas the parental strains 1026b and K96243 and the complemented mutants Bp410 and Bp454 were virulent in BALB/c mice following intranasal inoculation, the ΔpurM mutants Bp82 and Bp190 were avirulent even when they were administered at doses 4 logs higher than the doses used for the parental strains. Animals challenged with high doses of the ΔpurM mutants rapidly cleared the bacterium from tissues (lung, liver, and spleen) and remained free of culturable bacteria for the duration of the experiments (up to 60 days postinfection). Moreover, highly susceptible 129/SvEv mice and immune incompetent mice (IFN-γ?/?, SCID) were resistant to challenges with ΔpurM mutant Bp82. This strain was also avirulent in the Syrian hamster challenge model. We concluded that ΔpurM mutant Bp82 is fully attenuated and safe for use under BSL-2 laboratory conditions and thus is a candidate for exclusion from the select-agent list.
机译:伪疟原虫(Burkholderia pseudomallei)在人类中引起类鼻疽病,被分类为B类选择剂。在美国,对这种病原体的研究受到严格监管,甚至必须在生物安全3级(BSL-3)设施中进行基础研究。当前,没有可用的减毒假苹果芽孢杆菌菌株被选择剂法规排除,并且可以在BSL-2设施中安全处理。为了满足此需求,我们创建了Bp82和Bp190,它们是假性马来芽孢杆菌菌株1026b和K96243的ΔpurM衍生物,它们缺乏腺嘌呤和硫胺素的生物合成,但能够在丰富的培养基中体外复制。进行了一系列动物攻毒研究,以确保这些菌株被完全减毒。鼻内接种后,亲代菌株1026b和K96243以及互补的突变体Bp410和Bp454在BALB / c小鼠中具有毒性,即使ΔpurM突变体Bp82和Bp190的剂量均比亲本使用的剂量高4个对数,也无毒株。用高剂量的ΔpurM突变体攻击的动物会迅速从组织(肺,肝和脾)清除细菌,并在实验期间(感染后长达60天)保持无可培养细菌。此外,高度易感的129 / SvEv小鼠和免疫能力不强的小鼠(IFN-γ/α,SCID)对ΔpurM突变体Bp82的攻击具有抗性。该菌株在叙利亚仓鼠挑战模型中也没有毒力。我们得出的结论是,ΔpurM突变体Bp82在BSL-2实验室条件下可完全减毒并且可以安全使用,因此是从选择试剂列表中排除的候选对象。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号